Legend CEO spells out path to $5B in sales for multiple myeloma CAR-T therapy Carvykti
Approved in February as a fifth-line treatment for adults with relapsed or refractory multiple myeloma, J&J and Legend’s CAR-T therapy Carvykti may not have started out of the gate with a blockbuster niche, pulling in just $55 million in its first quarter.
But just wait, Legend CEO Ying Huang explained at a Jefferies event in London this week.
Over the next three to four years, according to a Jefferies analyst note from this morning, Huang said they are gearing up for a major manufacturing overhaul that will allow the companies to pull in more than $5 billion from Carvykti, the second BCMA CAR-T approved by the FDA.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.